ClinicalTrials.gg
Active, not recruitingNCT05327452Updated Jan 21, 2026

Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study

An interventional study of Supervised Home-Based Exercise and Unsupervised Home-Based Exercise in Breast Cancer, Colorectal Cancer and Prostate Cancer, sponsored by Dana-Farber Cancer Institute. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute — 15 open to participants now, 43 under way, none of them phase 3. Breast Neoplasms · Dana-Farber Cancer Institute.

Planned enrollment
29th of 132
135 · median 50
Started
2022
with 3 others
No phase
52 of 142
6 open now
Primary completion
2026-12
later than 19 of 42 live
Registered
123rd of 142
by date

Among the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute, this one is the 29th largest by planned enrollment of the 132 interventional ones that give a count, is one of 4 that started in 2022, is one of 52 with no phase, reaches primary completion later than 19 of the 42 other live ones, and was the 123rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute are open now, in 2 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

The purpose of this research is to determine whether a 16 week, home-based, aerobic and resistance exercise intervention will increase physical activity levels in Black and Hispanic breast, colorectal, or prostate cancer patients.

The names of the study interventions involved in this study are:

  • Supervised aerobic and resistance exercise (SUP) - virtually supervised 16- week aerobic and resistance exercise performed at home via Zoom.
  • Unsupervised aerobic and resistance exercise (UNSUP) - home-based 16- week aerobic and resistance exercise.
  • Attention control (AC) - 16-week home-based stretching.
Read the detailed description

This is a randomized control trial of Black and Hispanic patients who have been newly diagnosed with breast, colorectal, or prostate cancer and are being prescribed chemotherapy to determine the effects of home-based exercise on levels of physical activity. It will also evaluate the impact of home-based exercise on cardiovascular (heart health) risk factors.

The research study procedures include: screening for eligibility and study treatment including evaluations of body composition, blood tests, fitness and strength assessments, and surveys at study entry and follow-up visits.

Participants in this study will be randomly assigned to one of three groups: 1) Supervised aerobic and resistance exercise (SUP), 2) Unsupervised aerobic and resistance exercise (UNSUP), or 3) Attention control (AC).

Participation is expected to last for 8 months.

It is expected that about 135 people will take part in this research study.

03

Conditions studied

  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer

Keywords

  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 18 years old; children under the age of 18 will be excluded due to rarity of disease
  • Newly diagnosed with stage I-III breast, colorectal or prostate cancer
  • Self-identify as Hispanic or Black
  • Are within 4 weeks of initiating chemotherapy
  • Overweight or obese ( >25kg/m2 or body fat percent >30)
  • Physician's clearance to participate in moderate-vigorous intensity exercise
  • Speak English or Spanish
  • Engaging in less than 90 minutes of moderate-or-vigorous physical activity per week
  • Willing to travel to Dana-Farber Cancer Institute for necessary data collection
  • Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Pre-existing musculoskeletal or cardiorespiratory conditions
  • Patients should not have any uncontrolled illness including ongoing or active infection, uncontrolled diabetes, hypertension, or thyroid disease
  • Patients with other active
  • Patients with disease
  • Participate in more than 90 minutes of structured exercise/week
  • Unable to travel to Dana-Farber Cancer Institute for necessary data collection
  • Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    Supervised aerobic and resistance exercise (SUP)

    Participants will be randomly assigned to receive 3x weekly at home, virtually supervised aerobic and resistance exercise sessions with a certified exercise trainer for 16 weeks. Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit.

    Behavioral: Supervised Home-Based Exercise

  • Experimental
    Unsupervised aerobic and resistance exercise (UNSUP)

    Participants will be randomly assigned to receive 3x weekly at home, unsupervised aerobic and resistance exercise sessions with a 1x weekly telehealth call with a certified exercise trainer for 16 weeks. Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit.

    Behavioral: Unsupervised Home-Based Exercise

  • Active comparator
    Attention Control (AC)

    Participants will be randomly assigned to receive 3x weekly at home stretching exercise for 16 weeks. Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit.

    Behavioral: Attention Control

Interventions

  • BehavioralSupervised Home-Based Exercise

    Online supervised aerobic and resistance exercise

  • BehavioralUnsupervised Home-Based Exercise

    Unsupervised aerobic and resistance exercise (UNSUP)

  • BehavioralAttention Control

    Stretching Program

06

What researchers measure

Primary outcomes

  1. Change in Physical Activity Participation

    Changes from baseline in physical activity participation measured by Godin Leisure-Time Exercise Questionnaire.

    Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up

Secondary outcomes

  1. Biomarkers for Cardiovascular and Metabolic Health - insulin

    Fasting blood will be drawn from the antecubital vein by a trained phlebotomist. Insulin will be measured.

    Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up

  2. Blood Pressure

    Blood pressure will be assessed using an automated blood pressure cuff to measure both systolic and diastolic blood pressure.

    Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up

  3. Body Composition

    Body composition (lean mass and fat mass) will be assessed via bioelectrical impedance using a validated scale.

    Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up

  4. Cardiopulmonary Fitness

    Cardiopulmonary fitness will be measured by a submaximal graded exercise cycling test.

    Time frame: Evaluated at week 1 for baseline, week 9 for mid-point, week 16 for post-intervention assessment, and week 32 for follow-up

  5. Physical Fitness

    Physical Fitness will be measured by the short physical performance battery (SPPB).

    Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up

  6. Cardiorespiratory Fitness

    Cardiorespiratory fitness will be assessed by the 6-minute walk test.

    Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up

  7. Muscular Strength

    Muscular strength will be assessed with a 10 repetition maximum test.

    Time frame: Evaluated at week 1 for baseline, week 9 for mid-point, week 16 for post-intervention assessment, and week 32 for follow-up

  8. Patient Reported Outcomes - Quality of Life

    Quality of life will be assessed by EORTC QLQ C-30.

    Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up

  9. Patient Reported Outcomes - Health-related domains

    Health-related domains of patient reported outcomes will be assessed by PROMIS-29 Profile v2.1.

    Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up

  10. Patient Reported Outcomes - Sleep

    Quality of life will be assessed by the Pittsburg Sleep Quality Index (PSQI).

    Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up

  11. Patient Reported Outcomes - Symptoms

    Symptomatic toxicities will be assessed by PRO-CTCAE.

    Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up

  12. Dietary Assessment

    Dietary recall will be used to assess recent dietary patterns for two weekdays and one weekend day using NutriBase 11.

    Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up

  13. Acceptability of Intervention Questionnaire Ratings

    Intervention acceptability and feasibility will be assessed via Acceptability of Intervention and Feasibility of Intervention questionnaires. Items are measured on a 5-point Likert scale (completely disagree to completely agree). Score is calculated mean. An average rating of 4 or higher will be considered feasible/acceptable.

    Time frame: Evaluated at months 2 and 4

  14. Feasibility of Intervention Questionnaire Ratings

    Intervention acceptability and feasibility will be assessed via Acceptability of Intervention and Feasibility of Intervention questionnaires. Items are measured on a 5-point Likert scale (completely disagree to completely agree). Score is calculated mean. An average rating of 4 or higher will be considered feasible/acceptable.

    Time frame: Evaluated at months 2 and 4

  15. Augmentation Index

    Augmentation index (a marker for arterial stiffness) will also be assessed using Mobil-O-Graph device.

    Time frame: Time Frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up

  16. Biomarkers for Cardiovascular and Metabolic Health - glucose

    Fasting blood will be drawn from the antecubital vein by a trained phlebotomist. Glucose will be measured.

    Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up

  17. Biomarkers for Cardiovascular and Metabolic Health - HbA1c

    Fasting blood will be drawn from the antecubital vein by a trained phlebotomist. HbA1c will be measured.

    Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up.

  18. Biomarkers for Cardiovascular and Metabolic Health - c-peptide

    Fasting blood will be drawn from the antecubital vein by a trained phlebotomist. C-peptide (biomarkers of glycemic control and insulin resistance) will be measured.

    Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up.

  19. Biomarkers for Cardiovascular and Metabolic Health - c-reactive protein

    Fasting blood will be drawn from the antecubital vein by a trained phlebotomist. C-reactive protein (CRP; biomarker of system inflammation) will be measured.

    Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up.

07

Study locations

2 sites
08

References and documents

Publications

  • Yan H, Gonzalo-Encabo P, Wilson RL, Christopher CN, Cannon JD, Kang DW, Gardiner J, Perez M, Norris MK, Gundersen D, Hayman LL, Freedman RA, Rebbeck TR, Shi L, Dieli-Conwright CM. Testing home-based exercise strategies in underserved minority cancer patients undergoing chemotherapy (THRIVE) trial: a study protocol. Front Oncol. 2024 Sep 16;14:1427046. doi: 10.3389/fonc.2024.1427046. eCollection 2024. PubMed 39351353 ↗

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Dec 2026, 50 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 50 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2022
First posted
Apr 14, 2022
StartActual
Oct 31, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
May 31, 2027
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05327452
Collaborators
National Cancer Institute (NCI), University of Massachusetts, Boston
Responsible party
Christina Dieli-Conwright, PhD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Apr 14, 2022
Start date
Oct 31, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jan 21, 2026

Study contacts

Christina Dieli-Conwright, PhD, MPH
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion